Covaxin led to tolerable safety outcomes & enhanced immune responses, says Lancet
Even as a controversy rages over the safety of India’s first indigenous Covid-19 vaccine Covaxin after it was granted Emergency Use Authorisation (EUA) even as Phase III efficacy trials are underway, renowned medical journal Lancet said the vaccine, codenamed BBV152, led to tolerable safety outcomes and enhanced immune responses. “The overall incidence of solicited local and systemic adverse events in this study was 14-21% in all vaccine-treated groups, which is noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates.”
💡 newsR Knowledge: Other News Mentions
Mexico experts recommend approving Indian vaccineA technical committee of experts in Mexico gave a unanimous favorable opinion Friday on approving the Covaxin vaccine made by the Indian pharmaceutical company..
Govt sees Covaxin efficacy as validation of its scientific processThe phase 3 results of Covaxin released on Wednesday showing 81% efficacy is seen by the government as a major validation of the scientific process and..
Covid vaccine explained: Covishield? Covaxin? Do's and Don'ts | Oneindia News
Credit: Oneindia Duration: 03:13Published
Covaxin has 81% interim vaccine efficacy - here's what it meansThe trials for the third phase of the vaccine involved 25,800 subjects and it was the largest ever conducted in India.
COVID-19: THESE government employees to be reimbursed for vaccine 'medical expenses'Government has decided that employees who are insured by United India Insurance Corporation Limited, will be reimbursed the Covid 19 vaccination cost.
Covid-19 lockdown linked to uptick in tobacco use: Study
Credit: ANI Duration: 01:13Published
You Might Like
Related news from verified sources